Related Experiment Video
Updated: Jul 17, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
A knock-in mouse model for GABRG2-related epileptic encephalopathy displays spontaneous generalized seizures and
Dingding Shen1, Jiali Wan2, Xin Zhang2
1Department of Neurology in Affiliated Hospital of Nantong University, Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Medical School, Co-innovation Center of Neuroregeneration, Nantong University, Nantong, China.
Abstract:
De novo mutations in voltage- and ligand-gated ion channels have been associated with an increasing number of cases of developmental and epileptic encephalopathies (DEEs), which often fail to respond to classic antiseizure medications. A de novo mutation (c.C316G > A, p.A106T) in the human GABA type-A receptor γ2 subunit gene (GABRG2) has been recurrently identified in patients with DEE. In this study, we generated a knock-in mouse model replicating the human GABRG2(A106T) variation (Gabrg2+/A105T in mouse). Gabrg2+/A105T mice displayed early mortality, spontaneous seizures, and heightened seizure susceptibility. Behavioral analysis revealed phenotypes consistent with DEE, including impaired spatial learning and memory, as well as increased anxiety-like behavior. Reduced γ2 subunit protein expression was detected in the hippocampus of mutant mice, but not other brain regions. Electrophysiological recordings revealed a significant decrease in the amplitude of miniature inhibitory postsynaptic currents (mIPSCs), indicating impaired synaptic GABAergic inhibition. Notably, hippocampal transcriptome profiling provided evidence of neuroinflammation, and histological analysis demonstrated neuronal loss and microglia activation prior to seizure onset. These findings indicate that neuroinflammatory processes, a major theme in acquired epilepsies, may potentially exacerbate epileptogenesis in Gabrg2+/A105T mice. The knock-in mouse model serves as a potential model for evaluating anti-inflammatory therapies as adjunct treatments for drug-resistant DEEs.
Insights
A new mouse model with a GABRG2 gene mutation shows early mortality, seizures, and cognitive deficits, mimicking developmental and epileptic encephalopathies (DEEs). Neuroinflammation and impaired GABAergic inhibition contribute to the condition, suggesting potential anti-inflammatory treatments.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- De novo mutations in ion channels are linked to developmental and epileptic encephalopathies (DEEs).
- A specific GABRG2 mutation (p.A106T) is recurrently found in DEE patients.
- Many DEEs are resistant to conventional antiseizure medications.
Purpose of the Study:
- To create and characterize a knock-in mouse model of the human GABRG2(A106T) mutation.
- To investigate the underlying mechanisms of DEE associated with this mutation.
- To explore potential therapeutic strategies for drug-resistant DEEs.
Main Methods:
- Generated a Gabrg2 knock-in mouse model (Gabrg2+/A105T).
- Conducted behavioral analyses, electrophysiological recordings, and histological assessments.
- Performed hippocampal transcriptome profiling.
Main Results:
- Gabrg2+/A105T mice exhibited early mortality, spontaneous seizures, and heightened seizure susceptibility.
- Impaired spatial learning, memory, and increased anxiety were observed.
- Reduced γ2 subunit expression, decreased mIPSC amplitude, neuroinflammation, neuronal loss, and microglia activation were detected.
Conclusions:
- The GABRG2(A106T) mutation leads to impaired synaptic GABAergic inhibition and neuroinflammation.
- Neuroinflammation may exacerbate epileptogenesis in this DEE model.
- The Gabrg2+/A105T mouse is a valuable model for testing anti-inflammatory therapies in drug-resistant DEEs.
More Related Videos
11:54Simultaneous Video-EEG-ECG Monitoring to Identify Neurocardiac Dysfunction in Mouse Models of Epilepsy
Published on: January 29, 2018
09:29Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
Published on: August 17, 2021